scholarly journals Effect of tranilast ophthalmic solution on allergic conjunctivitis in guinea pigs.

1993 ◽  
Vol 101 (1) ◽  
pp. 27-32 ◽  
Author(s):  
Fumiaki ITOH ◽  
Yoshimitsu KOMATSU ◽  
Fumie TAYA ◽  
Masayuki ISAJI ◽  
Masami KOJIMA ◽  
...  
2009 ◽  
Vol 35 (1) ◽  
pp. 26-31 ◽  
Author(s):  
Kelly K. Nichols ◽  
Scot Morris ◽  
Ian B. Gaddie ◽  
David Evans

2007 ◽  
Vol 28 (4) ◽  
pp. 427-433 ◽  
Author(s):  
Mark B. Abelson ◽  
Paul J. Gomes ◽  
Terri Pasquine ◽  
Michael R. Edwards ◽  
Robert D. Gross ◽  
...  

1970 ◽  
Vol 12 (3) ◽  
pp. 156-158
Author(s):  
Ozlem Gurses Sahin

Aim: To evaluate whether a significant difference exists between the initial and final mean central corneal thickness that might affect Goldmann applanation tonometer recordings of patients with allergic conjunctivitis treated with desonide 0.25% ophthalmic solution, and to determine the effect of desonide on intraocular pressure by using adjusted intraocular pressure values.Methods: This double-blind randomised placebo-controlled trial enrolled 30 patients (60 eyes) with allergic conjunctivitis. Patients were randomly assigned to receive desonide to 1 eye (study eye) and preservative-free tear supplement (Tears Naturale Free®) to the other eye (control eye) 3 times daily for 3 weeks. Goldmann applanation tonometry and central corneal thickness of both eyes were recorded on the day of presentation and 3 weeks later.Results: Regression of itching, tearing, conjunctival hyperaemia, and tarsal conjunctival papillary reaction were noted in the study eyes after 3 weeks of treatment. The control eyes showed mild regression of pruritis, tearing, conjunctival hyperaemia, and tarsal conjunctival papillary reaction after 3 weeks. There was a significant difference between the initial and final mean central corneal thickness values for the study eyes (p = 0.003). There were no statistically significant differences between the initial and final mean values of Goldmann applanation tonometry and adjusted intraocular pressure for the study eyes. No statistically significant differences were found between the initial and final mean values of any of the parameters for the control eyes.Conclusion: Inflammation-induced increase in central corneal thickness of patients with allergic conjunctivitis treated with desonide showed statistically significant regression. However, this regression did not significantly affect Goldmann applanation tonometry and adjusted intraocular pressure values of the treated eyes.


1991 ◽  
Vol 14 (8) ◽  
pp. 467-473 ◽  
Author(s):  
Chiaki KAMEI ◽  
Keiji IZUSHI ◽  
Kenji TASAKA

1998 ◽  
Vol 8 (4) ◽  
pp. 207-216 ◽  
Author(s):  
C. Richard ◽  
C. Trinquand ◽  
E. Bloch-Michel ◽  
F. Favennec ◽  
L. Helleboid ◽  
...  

Purpose The aim of the study was to assess the efficacy and safety of 0.05% levocabastine eyedrops (H1 receptor blocker given BID + vehicle BID) compared with 0.1% lodoxamide ophthalmic solution (mast-cell stabilizer instilled QID) in reducing ocular signs and symptoms of allergic conjunctivitis. Methods A randomized, double-masked, parallel-group study was conducted in seven centres in France, in which 93 patients suffering from seasonal or perennial allergic conjunctivitis were randomly allocated to either 0.05% levocabastine (n = 47) or 0.1% lodoxamide (n = 46) in both eyes for a 14-day period. Efficacy was evaluated by subjective (prickling, burning, photophobia, itching) and objective (redness, chemosis, eyelid edema, tearing) sign scores at visits on days 7 and 14, and from data noted daily by the patient in a self-evaluation form. Safety was assessed as tolerance upon instillation and adverse event reports. Results The ocular allergy symptom and sign scores were comparable in the two treatment groups at baseline. With time, statistically and clinically significant reductions (p < 0.001) from baseline were observed for the subjective and objective scores, with no difference between the treatment groups. After the first instillation, signs were alleviated more rapidly in levocabastine-treated patients than in the lodoxamide group (p < 0.001). Overall assessments by the patient and investigator were similar in both groups. No serious adverse events were reported. Conclusions Levocabastine ophthalmic suspension 0.05% (BID) appears to be as effective and safe as lodoxamide 0.1% (QID) in the management of allergic conjunctivitis.


1994 ◽  
Vol 64 ◽  
pp. 92
Author(s):  
Miwa Misawa ◽  
Chiaki Suganuma ◽  
Tomokazu Hosokawa ◽  
Reiko Honma ◽  
Yoshitaka Ino ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document